NCT03366181View on ClinicalTrials.gov

SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

November 20, 2017

Study Completion Date

November 26, 2017

Conditions
Heart FailureICDDiabetes Mellitus Type 2SGLT2i
Trial Locations (1)

80128

Raffaele Marfella, Naples

All Listed Sponsors
lead

University of Campania Luigi Vanvitelli

OTHER

NCT03366181 - SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths. | Biotech Hunter | Biotech Hunter